Active Biotech AB Interim report January – June 2012

* Laquinimod – application submitted for regulatory approval in the EU resulting in milestone payment of USD 5 M
                   during third quarter 2012   
                 – a Phase III study will be initiated in the US       
* TASQ        – milestone payment of EUR 10 M received from Ipsen in connection with meeting patient enrolment target
                   for Phase III study
                 – overall survival data from Phase II study presented
* ANYARA   – Phase III trial continuing according to plan
* 57-57        – a clinical trial in systemic sclerosis/scleroderma in progress
* ISI             – project proceeding as planned
* The organization has been adapted to the company’s new direction
* Net sales: SEK 96.6 M (228.8)
* Operating loss: SEK 120.6 M (profit: 70.6)
* Loss after tax: SEK 123.5 M (profit: 77.7)
* Loss per share for the period: SEK 1.79 (earnings: 1.14)

 

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95    

Hans Kolam     
CFO     
Tel: +46 (0)46 19 20 44     

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00 

This report is also available at www.activebiotech.com   Fax: +46 (0)46 19 11 00

Active Biotech AB Interim report Jan – June 2012


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE
HUG#1633117